← All trials
NCT07053345
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 9, 2025
- Primary completion
- Jun 25, 2027
- Completion date
- Jun 25, 2027
- First posted
- Jul 8, 2025
- Last posted
- Nov 7, 2025
- Enrollment
- 47
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Janssen Pharmaceutica NVLead sponsor
- Janssen Pharmaceutica NVOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.